Design Therapeutics Income Statement (2020-2026) | DSGN

Income Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Revenue & Cost
Revenue (Quarter)
Interest income
Interest Income - Total (Quarter)
3.29M3.25M3.21M3.04M2.70M2.49M2.31M2.17M2.07M2.01M
Interest expenses
Interest Expenses (Quarter)
4.63M1.32M4.83M3.86M1.52M4.17M2.00M1.28M42.44M2.19M2.21M2.27M2.64M2.54M2.74M2.27M2.19M3.36M3.22M
Interest Income - Net (Quarter)
1.10M1.04M0.94M0.41M0.16M-0.25M0.05M-0.01M-1.29M-1.21M
Operating Items
Research & Development (Quarter)
8.54M7.34M8.76M11.29M14.30M14.26M15.73M17.06M13.26M11.01M9.80M10.52M11.88M12.16M15.38M15.74M14.59M-45.60M14.38M16.39M
Wages, Salaries and Other (Quarter)
0.10M0.22M0.22M0.23M0.26M0.25M0.26M
Selling, General & Administrative (Quarter)
2.80M3.79M4.61M4.34M4.89M5.14M5.92M5.53M5.57M4.11M4.60M4.53M4.37M4.54M5.04M5.83M0.06M4.74M5.33M5.79M
Other Operating Expenses (Quarter)
4.66M59.03M
Operating Expenses (Quarter)
11.34M11.13M13.37M15.64M19.19M19.39M21.65M22.60M18.82M15.12M14.40M15.04M16.25M16.69M20.42M21.57M19.31M18.17M19.71M22.18M
Operating Income (Quarter)
-11.34M-11.13M-13.37M-15.64M-19.19M-19.39M-21.65M-22.60M-18.82M-15.12M-14.40M-15.04M-16.25M-16.69M-20.42M-21.57M-19.31M-18.17M-19.71M-22.18M
EBIT (Quarter)
-11.34M-11.13M-13.37M-15.64M-19.19M-19.39M-21.65M-22.60M-18.82M-15.12M-14.40M-15.04M-16.25M-16.69M-20.42M-21.57M-19.31M-18.17M-19.71M-22.18M
Non-operating items
Interest & Investment Income (Quarter)
0.01M-0.24M-1.08M-0.99M-1.55M0.51M1.37M-0.02M0.72M9.26M3.29M3.25M3.21M3.04M2.70M2.49M2.31M2.17M2.07M2.01M
Other Non Operating Income (Quarter)
0.02M0.06M0.10M0.64M1.49M2.05M2.36M2.66M3.03M3.28M3.29M3.25M3.21M
Net income details
EBT (Quarter)
-15.96M-11.37M-15.77M-21.46M-24.60M-20.41M-24.45M-24.62M-19.39M-48.30M-13.30M-14.00M-15.31M-16.29M-20.26M-21.82M-19.27M-18.18M-20.99M-23.39M
Profit After Tax (Quarter)
-11.32M-11.46M-13.27M-15.99M-19.25M-17.34M-19.29M-19.94M-15.79M-11.84M-11.11M-11.79M-13.04M-13.65M-17.71M-19.08M-17.00M-16.00M-17.64M-20.16M
Income from Continuing Operations (Quarter)
-15.96M-11.37M-15.77M-21.46M-24.60M-20.41M-24.45M-24.62M-19.39M-48.30M-13.30M-14.00M-15.31M-16.29M-20.26M-21.82M-19.27M-18.18M-20.99M-23.39M
Consolidated Net Income (Quarter)
-15.96M-11.37M-15.77M-21.46M-24.60M-20.41M-24.45M-24.62M-19.39M-48.30M-13.30M-14.00M-15.31M-16.29M-20.26M-21.82M-19.27M-18.18M-20.99M-23.39M
Income towards Parent Company (Quarter)
-15.96M-11.37M-15.77M-21.46M-24.60M-20.41M-24.45M-24.62M-19.39M-48.30M-13.30M-14.00M-15.31M-16.29M-20.26M-21.82M-19.27M-18.18M-20.99M-23.39M
Net Income towards Common Stockholders (Quarter)
-15.96M-11.37M-15.77M-21.46M-24.60M-20.41M-24.45M-24.62M-19.39M-48.30M-13.30M-14.00M-15.31M-16.29M-20.26M-21.82M-19.27M-18.18M-20.99M-23.39M
Additional items
EPS (Basic) (Quarter)
-0.29-0.25-0.28-0.39-0.44-0.37-0.44-0.44-0.35-0.86-0.24-0.25-0.27-0.29-0.36-0.38-0.34-0.32-0.34-0.37
EPS (Diluted) (Quarter)
-0.29-0.25-0.28-0.39-0.44-0.37-0.44-0.44-0.35-0.86-0.24-0.25-0.27-0.29-0.36-0.38-0.34-0.32-0.34-0.37
Shares Outstanding (Quarter)
55.16M45.94M55.51M55.67M55.78M55.71M55.91M55.95M55.99M55.98M56.49M56.56M56.62M56.59M56.76M56.86M56.95M57.33M61.43M62.51M
Shares Outstanding (Diluted) (Quarter)
55.16M45.94M55.51M55.67M55.78M55.71M55.91M55.95M55.99M55.98M56.49M56.56M56.62M56.59M56.76M56.86M56.95M57.33M61.43M62.51M
Shares Outstanding (Entity) (Quarter)
55.22M45.94M55.62M55.72M55.84M55.90M55.92M55.98M56.00M56.47M56.49M56.62M56.62M56.75M56.77M56.95M56.96M60.40M62.44M62.58M
EBITDA (Quarter)
-11.34M-11.13M-13.37M-15.64M-19.19M-19.39M-21.65M-22.60M-18.82M-15.12M-14.40M-15.04M-16.25M-16.69M-20.42M-21.57M-19.31M-18.17M-19.71M-22.18M